We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Amgen's MariTide Take on Leaders in the Obesity Space?
Read MoreHide Full Article
Key Takeaways
Amgen completed MARITIME-1 and -2 enrollment, testing MariTide in 5,000 obesity patients.
MariTide aims for monthly or less frequent dosing, showing sustained weight loss in studies.
NVO won FDA approval for an oral Wegovy pill, raising competition as oral GLP-1s enter weight management.
Amgen (AMGN - Free Report) is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor agonist, as part of its comprehensive MARITIME phase III program in obesity. With this drug, Amgen intends to take on Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) , which currently dominate this space with their respective injectable GLP-1 therapies.
A key differentiator for MariTide is its long-acting profile. Unlike currently marketed GLP-1 drugs, such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which require weekly injections, MariTide is designed for monthly or potentially even less frequent dosing. Amgen has reported predictable and sustained weight loss, with clinically meaningful improvements in cardiometabolic parameters, in earlier studies, positioning MariTide as a potentially more convenient long-term treatment option in a market increasingly focused on adherence and durability.
Amgen is evaluating MariTide across a broad range of cardiometabolic indications, with obesity at the center of its development strategy. Enrollment has been completed in two pivotal late-stage studies — MARITIME-1 and MARITIME-2 — which are evaluating the drug in patients with obesity, with and without type II diabetes, respectively. Roughly 5,000 patients were enrolled across these studies in a relatively short time frame, underscoring strong investigator and patient interest in the program.
Apart from obesity, MariTide is also being studied in phase III studies for atherosclerotic cardiovascular disease and heart failure, as well as in obstructive sleep apnea. These indications could significantly expand the drug’s commercial potential if weight loss translates into downstream cardiometabolic and cardiovascular benefits, as suggested by earlier-stage data.
Market Leaders Continue to Raise the Bar
Despite MariTide’s differentiated dosing profile, the obesity treatment landscape is evolving rapidly. Recently, Novo Nordisk secured FDA approval for the pill version of Wegovy, marking approval for the first GLP-1 RA approved in an oral form for weight management. Compared with injectable formulations, the pill offers a far more convenient administration option, significantly lowering treatment burden and potentially improving patient adherence. Novo Nordisk expects to launch the Wegovy pill in early next month and has priced the drug at $149 per month for patients without insurance.
Eli Lilly is also moving quickly in this direction. Earlier this month, LLY submitted a regulatory filing seeking approval for its oral obesity candidate, orforglipron, setting the stage for a potential launch next year. The arrival of effective oral GLP-1 therapies raises the bar for differentiation and could reshape patient and physician preferences across the obesity market.
That said, this push for oral pills does not signal a retreat from injectables for either market leader. Eli Lilly continues to invest aggressively across next-generation obesity therapies with diverse mechanisms of action. Its pipeline includes orforglipron, a once-daily oral small-molecule GLP-1, as well as retatrutide, a triple-hormone (GIP/GLP-1/glucagon) agonist being developed as a next-generation injectable.
Novo Nordisk is similarly expanding its next wave of obesity treatments. It is advancing a next-generation therapy called amycretin, both as an injectable and an oral formulation. NVO plans to initiate a phase III program for amycretin in the first quarter of 2026, reinforcing its strategy of maintaining leadership across multiple modalities rather than relying on a single product class.
AMGN’s Price Performance, Valuation and Estimates
Shares of Amgen have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.20 times forward earnings compared to the industry's average of 17.56. The stock is trading above its five-year mean of 13.76.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have risen in the past 60 days.
Image: Bigstock
Can Amgen's MariTide Take on Leaders in the Obesity Space?
Key Takeaways
Amgen (AMGN - Free Report) is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing MariTide, an investigational GLP-1/GIP receptor agonist, as part of its comprehensive MARITIME phase III program in obesity. With this drug, Amgen intends to take on Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) , which currently dominate this space with their respective injectable GLP-1 therapies.
A key differentiator for MariTide is its long-acting profile. Unlike currently marketed GLP-1 drugs, such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which require weekly injections, MariTide is designed for monthly or potentially even less frequent dosing. Amgen has reported predictable and sustained weight loss, with clinically meaningful improvements in cardiometabolic parameters, in earlier studies, positioning MariTide as a potentially more convenient long-term treatment option in a market increasingly focused on adherence and durability.
Amgen is evaluating MariTide across a broad range of cardiometabolic indications, with obesity at the center of its development strategy. Enrollment has been completed in two pivotal late-stage studies — MARITIME-1 and MARITIME-2 — which are evaluating the drug in patients with obesity, with and without type II diabetes, respectively. Roughly 5,000 patients were enrolled across these studies in a relatively short time frame, underscoring strong investigator and patient interest in the program.
Apart from obesity, MariTide is also being studied in phase III studies for atherosclerotic cardiovascular disease and heart failure, as well as in obstructive sleep apnea. These indications could significantly expand the drug’s commercial potential if weight loss translates into downstream cardiometabolic and cardiovascular benefits, as suggested by earlier-stage data.
Market Leaders Continue to Raise the Bar
Despite MariTide’s differentiated dosing profile, the obesity treatment landscape is evolving rapidly. Recently, Novo Nordisk secured FDA approval for the pill version of Wegovy, marking approval for the first GLP-1 RA approved in an oral form for weight management. Compared with injectable formulations, the pill offers a far more convenient administration option, significantly lowering treatment burden and potentially improving patient adherence. Novo Nordisk expects to launch the Wegovy pill in early next month and has priced the drug at $149 per month for patients without insurance.
Eli Lilly is also moving quickly in this direction. Earlier this month, LLY submitted a regulatory filing seeking approval for its oral obesity candidate, orforglipron, setting the stage for a potential launch next year. The arrival of effective oral GLP-1 therapies raises the bar for differentiation and could reshape patient and physician preferences across the obesity market.
That said, this push for oral pills does not signal a retreat from injectables for either market leader. Eli Lilly continues to invest aggressively across next-generation obesity therapies with diverse mechanisms of action. Its pipeline includes orforglipron, a once-daily oral small-molecule GLP-1, as well as retatrutide, a triple-hormone (GIP/GLP-1/glucagon) agonist being developed as a next-generation injectable.
Novo Nordisk is similarly expanding its next wave of obesity treatments. It is advancing a next-generation therapy called amycretin, both as an injectable and an oral formulation. NVO plans to initiate a phase III program for amycretin in the first quarter of 2026, reinforcing its strategy of maintaining leadership across multiple modalities rather than relying on a single product class.
AMGN’s Price Performance, Valuation and Estimates
Shares of Amgen have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.20 times forward earnings compared to the industry's average of 17.56. The stock is trading above its five-year mean of 13.76.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have risen in the past 60 days.
Image Source: Zacks Investment Research
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.